Description
Atrial natriuretic peptide (ANP) (3-28) is a synthetic and truncated form of ANP, which is an endogenous peptide generated by proteolysis of prepro-ANP that is secreted by cardiomyocytes in the heart.1,2,3 ANP (3-28) potently inhibits renin release from cultured renal juxtaglomerular cells (Ki = 10 pM) in a cGMP-dependent manner.4 It also dose-dependently decreases mean arterial pressure (MAP) and arterial plasma renin activity and increases fractional sodium and calcium excretion, urine volume, and glomerular filtration rate in conscious dogs with a maximum effect attained when administered at a dose of 200 pM.5 ANP (3-28) (human) is a 26 amino acid peptide corresponding to the truncated human protein sequence.WARNING This product is not for human or veterinary use.
References
[1] T.GEOFFREY FLYNN Adolfo J de B Mercedes L de Bold. The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties[J]. Biochemical and biophysical research communications, 1983, 117 3: Pages 859-865. DOI: 10.1016/0006-291x(83)91675-3
[2] MAACK T. Role of atrial natriuretic factor in volume control[J]. Kidney international, 1996, 49 6: Pages 1732-1737. DOI: 10.1038/ki.1996.257
[3] KENJI KANGAWA Hisayuki M. Purification and complete amino acid sequence of α-human atrial natriuretic polypeptide (α-hANP)[J]. Biochemical and biophysical research communications, 1984, 118 1: Pages 131-139. DOI: 10.1016/0006-291x(84)91077-5
[4] A KURTZ. Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP-mediated process.[J]. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83 13: 4769-4773. DOI: 10.1073/pnas.83.13.4769
[5] A A SEYMOUR. A comparison of synthetic rat and human atrial natriuretic factor in conscious dogs.[J]. Hypertension, 1986, 8 3: 211-216. DOI: 10.1161/01.hyp.8.3.211
